BARDA Backs Arcturus' Influenza Vaccine Program
BARDA Backs Arcturus' Influenza Vaccine Program
Barda支持Arcturus的流感疫苗計劃
- Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) received an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA).
- The award provides three years to support preclinical, manufacturing, and nonclinical safety studies, along with development and regulatory support for Arcturus' self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 studies.
- Also see: Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants.
- The company says its self-amplifying mRNA vaccine has been administered to over 10,000 individuals globally, demonstrating favorable safety, strong immunogenicity, and protection against SARS-COV-2 infection.
- Price Action: ARCT shares are down 2.68% at $13.66 on the last check Thursday.
- Arcturus治療控股公司納斯達克(Sequoia Capital:ARCT)從生物醫學高級研究與發展局(BARDA)獲得了高達6,320萬美元的獎金。
- 該獎項為期三年,用於支持臨牀前、生產和非臨牀安全性研究,以及對Arcturus的自我放大信使核糖核酸疫苗平臺技術的開發和監管支持,以通過第一階段研究快速應對大流行性流感。
- 另請參閲: 大角星的新冠肺炎助推器對奧密克戎變種表現出耐用性.
- 該公司表示,其自我放大的mRNA疫苗已在全球超過1萬人接種,表現出良好的安全性、強大的免疫原性和對SARS-COV-2感染的保護作用。
- 價格行動:在週四的最後一次檢查中,ARCT的股價下跌了2.68%,至13.66美元。